Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 5, 2015, Pages 8288-8294

  Fu, Yan ^a   Kang, Huanrong ^a   Zhao, Hui ^a   Hu, Jia ^a   Zhang, Huanhuan ^a   Li, Xiaosong ^a   Du, Nan ^a   Huang, Yitao ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Dermatofibrosarcoma protuberan; Efficacy; Imatinib; Resistance; Sunitinib

Indexed keywords

IMATINIB; SUNITINIB;

ADULT; AGED; ANEMIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DERMATOFIBROSARCOMA PROTUBERANS; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; EDEMA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RASH; THROMBOCYTOPENIA; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME;

EID: 84937053788     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. [1] Gloster HM Jr. Dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996; 35: 355-374.
2. [2] Laskin WB. Dermatofibrosarcoma protuberans. CA Cancer J Clin 1992; 42: 116-125.
3. [3] Chang CK, Jacobs IA, Salti GI. Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 2004; 30: 341-345.
4. [4] Kimmel Z, Ratner D, Kim JY. Peripheral excision margins for dermatofibrosarcoma protuberans: a metaanalysis of spatial data. Ann Surg Oncol 2007; 14: 2113-2120.
5. [5] Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG. Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution. Cancer 2000; 15; 88: 2711-2720.
6. [6] Naeem R, Lux ML, Huang SF, Naber SP, Corson JM, Fletcher JA. Ring chromosomes in dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22. Am J Pathol 1995; 147: 1553-1558.
7. [7] O’Brien KP, Seroussi E, Dal Cin P. Various regions within the alphahelical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. Genes Chromosomes Cancer 1998; 23: 187-193.
8. [8] Nishio J, Iwasaki H, Ishiguro M. Supernumerary ring chromosome in a bednar tumor (pigmented dermatofibrosarcoma protuberans) is composed of interspersed sequences from chromosomes 17 and 22: a fluorescence in situ hybridization and comparative genomic hybridization analysis. Genes Chromosomes Cancer 2001; 30: 305-309.
9. [9] Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003; 37: 1-19.
10. [10] Takahira T, Oda Y, Tamiya S. Detection of COL1A1-PDGFB fusion transcripts and PDGFB/PDGFRB mRNA expression in dermatofibrosarcoma protuberans. Mod Pathol 2007; 20: 668-75.
11. [11] Patel KU, Szabo SS, Hernandez VS. Dermato-fibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 2008; 39: 184-193.
12. [12] Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007; 356: 115-124.
13. [13] Demetri GD, van Oosterom AT, Garrett CR. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: A randomized controlled trial. Lancet 2006; 14; 368: 1329-1338.
14. [14] Maki RG, Awan RA, Dixon RH. Differential sensitivity to Imatinib of 2 patients with metastatic sarcoma arising from Dermatosarcoma Protuberans. Int J Cancer 2002; 100: 623-626.
15. [15] Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004; 7: 225-233.
16. [16] Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471-478.
17. [17] Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
18. [18] Murray LJ, Abrams TJ, Long KR.SU11248 inhibits tumor growth and CSF-1R dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20: 757-766.
19. [19] O’Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-3605.
20. [20] Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003; 63: 4009-4016.
21. [21] Penot P, Bouaziz JD, Battistella M. Stabilization of multiple metastatic epithelioid sarcoma under treatment with sunitinib malate. Br J Dermatol 2013; 168: 871-873.
22. [22] Stacchiotti S, Negri T, Zaffaroni N. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol 2011; 22: 1682-1690.
23. [23] Suzanne George, Priscilla Merriam, Robert G. Maki. Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas. JCO 2009; 27: 3154-3160.
24. [24] Stacchiotti S, Negri T, Libertini M. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol 2012; 23: 3171-3179.
25. [25] Sun LM, Wang CJ, Huang CC. Dermato-fibrosarcoma protuberans: treatment results of 35 cases. Radiother Oncol 2000; 57: 175-181.
26. [26] Dagan R, Morris CG, Zlotecki RA. Radiotherapy in the treatment of dermatofibrosarcoma protuberans. Am J Clin Oncol 2005; 28: 537-539.
27. [27] McArthur GA, Demetri GD, van Oosterom A. Molecular and clinical analysis of locally advanced dermatofi brosarcoma protuberans treated with imatinib: Imatinib Target Ex-ploration Consortium Study B2225. J Clin Oncol 2005; 23: 866-873.
28. [28] Rutkowski P, Glabbeke MV, Rankin CJ. Imatinib mesylatein advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010; 28: 1772-1779.
29. [29] Jiahua Zhu, Qiuwen Li, Wenhua Xiao. Advanced Dermatofibrosarcoma Protuberan treated with imatinib mesylate. Chin J Onclo 2011; 33: 470-473.
30. [30] Breccia M, Alimena G. The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose. Expert Opin Pharmacother 2011; 12: 2075-2087.
31. [31] Quintás-Cardama A, Cortes J. Therapeutic options against BCR-ABL1T315I-positive chronic myelogenous leukemia. Clin Cancer Res 2008; 14: 4392-4399.
32. [32] Weisbeg E, Manley PW, Cowan-Jacob SW. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7: 345-356.
33. [33] Hong JY, Liu X, Mao M, Li M, Choi DI, Kang SW, Lee J, La Choi Y. Genetic Aberrations in Imatinib-Resistant Dermatofibrosarcoma Protuberans Revealed by Whole Genome Sequencing. PLoS One 2013; 8: e69752.
34. [34] Pan X, Mao T, Fang W, Chen W. Vascular endothelial growth factor C is an indicator of lymph node metastasis in thoracic esophageal squamous cell carcinomas and its role in long-term survival after surgery. Thoracic Cancer 2014; 5: 313-318.
35. [35] Zhuo Y, Guo Q, Song P, Zhang Q, Guo C, Zeng H, Guan Y, Liu X, Zhao C. Correlation study and significance of the EGFR expression in serum, lymph nodes and tumor tissue of NSCLC. Thoracic Cancer 2014; 5: 31-37.